BIO (June 2025)/ XFTTBIOCMEGL / CME EMini
BIO- - | Chg. - | Open | High | Low | Previous Close |
---|---|---|---|---|---|
-USD | - | - | - | - | - |
GlobeNewswire
10/05
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
GlobeNewswire
09/05
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
GlobeNewswire
09/05
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
08/05
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue
GlobeNewswire
07/05
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Los...
GlobeNewswire
07/05
BIO-key Wins Coveted Global InfoSec Award for Multi-factor Authentication During RSA Conference 2024
GlobeNewswire
07/05
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Ru...
GlobeNewswire
07/05
ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Impor...
GlobeNewswire
04/05
ROSEN, A LEADING NATIONAL FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities C...
GlobeNewswire
02/05
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire
02/05
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
GlobeNewswire
01/05
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue
GlobeNewswire
01/05
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
GlobeNewswire
01/05
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merge...
GlobeNewswire
01/05
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merge...
GlobeNewswire
01/05
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
GlobeNewswire
30/04
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of...
GlobeNewswire
30/04
BLUE LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire ...